A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)
Latest Information Update: 21 Oct 2021
Price :
$35 *
At a glance
- Drugs Guselkumab (Primary)
- Indications Palmoplantar pustulosis
- Focus Therapeutic Use
- 20 Oct 2021 Status changed from recruiting to completed.
- 05 Aug 2019 New trial record